Splenic marginal zone lymphoma epidemiology and demographics
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma epidemiology and demographics |
|
FDA on Splenic marginal zone lymphoma epidemiology and demographics |
|
CDC on Splenic marginal zone lymphoma epidemiology and demographics |
|
Splenic marginal zone lymphoma epidemiology and demographics in the news |
|
Blogs on Splenic marginal zone lymphoma epidemiology and demographics |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Splenic marginal zone lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [3]
Overview
The incidence of splenic marginal zone lymphoma increases with age; the median age at diagnosis is 65-70 years. Splenic marginal zone lymphoma affects men and women equally.
Epidemiology and demographics
Incidence
- Splenic marginal zone lymphoma represents less than 1% of all non-hodgkins lymphomas.[1][2]
- It constitutes around 20% of all marginal zone lymphomas (MZL).[3]
- The overall annual age adjusted incidence during 2001-2008 was 0.13/100,000 person per year that seems to gradually increasing with time.[4][5]
Age
- The incidence of splenic marginal zone lymphoma increases with age
- The median age at the time of diagnosis is 69 years.[6]
Race
- Splenic marginal zone lymphoma is more common in the white patient population..[2]
Gender
Splenic marginal zone lymphoma affects men and women equally.[7]
=
References
- ↑ Armitage JO, Weisenburger DD (August 1998). "New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project". J. Clin. Oncol. 16 (8): 2780–95. doi:10.1200/JCO.1998.16.8.2780. PMID 9704731.
- ↑ 2.0 2.1 Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL (July 2013). "Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States". Leuk. Lymphoma. 54 (7): 1380–6. doi:10.3109/10428194.2012.743655. PMID 23101590.
- ↑ Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (May 2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
- ↑ Olszewski AJ, Castillo JJ (February 2013). "Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database". Cancer. 119 (3): 629–38. doi:10.1002/cncr.27773. PMID 22893605.
- ↑ Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS (September 2015). "Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011". Am. J. Hematol. 90 (9): 790–5. doi:10.1002/ajh.24086. PMID 26096944.
- ↑ [1] Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." Blood. 2000 Mar 15;95(6):1950-6. PMID: 10706860
- ↑ Traverse-Glehen A, Baseggio L, Salles G, Felman P, Berger F (September 2011). "Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification". Curr Opin Oncol. 23 (5): 441–8. doi:10.1097/CCO.0b013e328349ab8d. PMID 21760505.